Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson Appoints Jessica Moore as Vice President of Investor Relations

10/13/2021 | 10:27am EST

Johnson & Johnson announced the appointment of Jessica Moore to Vice President of Investor Relations for Johnson Johnson, effective November 1, 2021. Ms. Moore will report to Mr. Joseph Wolk, Executive Vice President and Chief Financial Officer of the Company. Ms. Moore brings 20 years of strong, diverse and international financial experience spanning across Sales Operations, Corporate and Regional positions. Most recently, Ms. Moore served as the Vice President and Chief Financial Officer for the Janssen Pharmaceutical business in the EMEA Region where she played a critical role in the analysis of financial performance, assessment of risks and opportunities and maintenance of a strong compliant environment. Prior to joining Johnson Johnson, Ms. Moore held various leadership positions of increasing responsibilities at Baxter International, where she focused on returning the EMEA business to growth and led a transformational project to standardize and centralize financial processes across commercial and manufacturing entities.


ę S&P Capital IQ 2021
All news about JOHNSON & JOHNSON
10:21aZymeworks to Get Milestone Payment After Janssen Doses First Patient With Licensed Anti..
MT
09:34aJohnson & Johnson announces significant progress towards its climate goals - 100% renew..
AQ
11/30JOHNSON & JOHNSON : Janssen Seeks Approval of IMBRUVICA«(ibrutinib) in a Fixed-Duration Re..
PU
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11/30Johnson & Johnson Units, Aspen Pharmacare Sign Term Sheet for Manufacturing of COVID-19..
MT
11/30JOHNSON & JOHNSON : Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced St..
PU
11/30JOHNSON & JOHNSON : announces significant progress towards its climate goals – 100% ..
PU
11/30JOHNSON & JOHNSON : How Johnson & Johnson is Working to Create a Healthier Planet
PU
11/30Presidential Taskforce On Covid-19 Endorses Pfizer-BioNTtech Vaccine for 12+ Year Olds
AQ
11/29SCIENTISTS SCRAMBLE TO UNDERSTAND CO : What we know
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 251 M - -
Net income 2021 22 542 M - -
Net Debt 2021 493 M - -
P/E ratio 2021 18,8x
Yield 2021 2,67%
Capitalization 411 B 411 B -
EV / Sales 2021 4,36x
EV / Sales 2022 4,05x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 155,93 $
Average target price 184,65 $
Spread / Average Target 18,4%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871
ABBVIE INC.7.59%203 801